18F-FDG PET/CT uptake due to poly-L-lactic acid facial injections

Nuklearmedizin 2013; 52(06): N66-N67
DOI: 10.1055/s-0038-1625227

Case report

Schattauer GmbH

¹⁸F-FDG PET/CT uptake due to poly-L-lactic acid facial injections

¹⁸ F-FDG-PET/CT-Aufnahme aufgrund von Poly-L-Milchsäure-Gesichtsinjektionen

D. Métivier

¹Department of Nuclear Medicine, University Hospital Tenon, AP-HP & Université Pierre et Marie Curie (UPMC), Paris, France

,

F. Montravers

¹Department of Nuclear Medicine, University Hospital Tenon, AP-HP & Université Pierre et Marie Curie (UPMC), Paris, France

,

S. Balogova

¹Department of Nuclear Medicine, University Hospital Tenon, AP-HP & Université Pierre et Marie Curie (UPMC), Paris, France

²Comenius University, Bratislava, Slovakia

,

J.-N. Talbot

¹Department of Nuclear Medicine, University Hospital Tenon, AP-HP & Université Pierre et Marie Curie (UPMC), Paris, France

References
1 Barton SE, Engelhard P, Conant M. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies. Int J STD AIDS 2006; 17: 429-435.
2 Bassichis B, Blick G, Conant M. et al. Injectable poly-l-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). Dermatol Surg 2012; 38: 1193-1205.
3 James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28: 979-986.
4 Kates LC, Fitzgerald R. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review. Aesthet Surg J 2008; 28: 397-403.
5 Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol 2008; 59: 923-933.